Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report
Journal of International Medical Research, 2022 Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration.
Ping Huang, Yuhong Li
doaj +1 more source
Journal of Agromedicine and Medical Sciences (AMS), 2023 Polycythemia vera happened in people around 40-60 years old and mostly men. The criteria are total red blood cells ≥36 mL/kg in males, thrombocytosis, leukocytosis, and JAK2 mutation.
I Gusti Ayu Ratna Dewi +2 more
doaj +1 more source
Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]
Korean Journal of Anesthesiology, 2015 Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im +4 more
doaj +1 more source
Aberrant expression of microRNA in polycythemia vera
Haematologica, 2008 Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova +2 more
doaj +1 more source
Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
Haematologica, 2011 TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek +7 more
doaj +1 more source
Haematologica, 2008 We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon +8 more
doaj +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Haematologica, 2013 Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey +5 more
doaj +1 more source
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]
, 2018 We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo +41 more
core +5 more sources
All we know about polycythemia vera: literature review and own experience
Онкогематология, 2015 The literature review and own long-term polycythemia vera diagnosis and treatment experience are presented in this article. The results of newest advances in pathogenesis description, modern diagnostic techniques and treatment modalities in polycythemia ...
K. M. Abdulkadyrov +2 more
doaj +1 more source